专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09833476B2 NKP30 receptor targeted therapeutics 有权
公开(公告)号：US09833476B2
公开(公告)日：2017-12-05
申请号：US14342060
申请日：2012-08-31
申请人： Tong Zhang , Charles L. Sentman
发明人： Tong Zhang , Charles L. Sentman
IPC分类号： C07K14/70 , A61K35/17 , C07K14/705 , C12N5/0783 , A61K38/00
CPC分类号： A61K35/17 , A61K38/00 , C07K14/70503 , C07K14/70521 , C07K14/70575 , C07K14/70578 , C07K14/70596 , C07K2319/00 , C07K2319/03 , C12N5/0636 , C12N2800/22
摘要： The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

2. 发明授权

US09273283B2 Method of producing T cell receptor-deficient T cells expressing a chimeric receptor 有权
标题翻译：产生表达嵌合受体的T细胞受体缺陷型T细胞的方法
公开(公告)号：US09273283B2
公开(公告)日：2016-03-01
申请号：US13459664
申请日：2012-04-30
申请人： Charles L. Sentman
发明人： Charles L. Sentman
IPC分类号： C12N15/00 , C12N5/0783 , A61K39/00
CPC分类号： C12N5/0636 , A61K2039/5156 , C12N2501/515
摘要： The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
摘要翻译：本发明涉及修饰的T细胞，制备和使用分离的，修饰的T细胞的方法，以及使用这些分离的，修饰的T细胞来解决疾病和病症的方法。在一个实施方案中，本发明广泛涉及TCR缺陷的T细胞，其分离的群体，以及包含其的组合物。在本发明的另一个实施方案中，将这些TCR缺陷型T细胞设计为表达功能性非TCR受体。本发明还涉及制备所述TCR缺陷型T细胞的方法，以及使用所述TCR缺陷型T细胞，其群体或包含该T细胞的组合物减少或改善或预防或治疗疾病和病症的方法。

3. 发明授权

US08252914B2 Chimeric NK receptor and methods for treating cancer 有权
标题翻译：嵌合NK受体和治疗癌症的方法
公开(公告)号：US08252914B2
公开(公告)日：2012-08-28
申请号：US13155909
申请日：2011-06-08
申请人： Tong Zhang , Charles L. Sentman
发明人： Tong Zhang , Charles L. Sentman
IPC分类号： C12N15/11 , C12N15/63 , C12N15/85
CPC分类号： C07K14/705 , A61K35/17 , A61K38/10 , A61K45/06 , C07K14/715
摘要： The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
摘要翻译：本发明涉及用于减少或消除肿瘤的嵌合免疫受体分子。嵌合受体是与含有基于免疫受体酪氨酸的活化基序的免疫信号受体融合的C型凝集素样天然杀伤细胞受体或与其相关的蛋白质。还提供了使用嵌合受体的方法。

4. 发明申请

US20100029749A1 Chimeric NK Receptor and Methods for Treating Cancer 有权
标题翻译：嵌合NK受体和治疗癌症的方法
公开(公告)号：US20100029749A1
公开(公告)日：2010-02-04
申请号：US11575878
申请日：2005-08-31
申请人： Tong Zhang , Charles L. Sentman
发明人： Tong Zhang , Charles L. Sentman
IPC分类号： A61K31/7088 , C07H21/04 , A61P35/00 , C12N15/74
CPC分类号： C07K14/705 , A61K35/17 , A61K38/10 , A61K45/06 , C07K14/715
摘要： The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
摘要翻译：本发明涉及用于减少或消除肿瘤的嵌合免疫受体分子。嵌合受体是与含有基于免疫受体酪氨酸的活化基序的免疫信号受体融合的C型凝集素样天然杀伤细胞受体或与其相关的蛋白质。还提供了使用嵌合受体的方法。

5. 发明申请

US20090202501A1 Chimeric NK receptor and methods for treating cancer 审中-公开
标题翻译：嵌合NK受体和治疗癌症的方法
公开(公告)号：US20090202501A1
公开(公告)日：2009-08-13
申请号：US12407440
申请日：2009-03-19
申请人： Tong Zhang , Charles L. Sentman
发明人： Tong Zhang , Charles L. Sentman
IPC分类号： A61K35/12 , C12N15/63 , C12N5/00
CPC分类号： C07K14/705 , A61K35/17 , A61K38/10 , A61K45/06 , C07K14/715
摘要： The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
摘要翻译：本发明涉及用于减少或消除肿瘤的嵌合免疫受体分子。嵌合受体是与含有基于免疫受体酪氨酸的活化基序的免疫信号受体融合的C型凝集素样天然杀伤细胞受体或与其相关的蛋白质。还提供了使用嵌合受体的方法。

6. 发明授权

US09181527B2 T cell receptor-deficient T cell compositions 有权
标题翻译： T细胞受体缺陷型T细胞组合物
公开(公告)号：US09181527B2
公开(公告)日：2015-11-10
申请号：US13502978
申请日：2010-10-29
申请人： Charles L. Sentman
发明人： Charles L. Sentman
IPC分类号： C12N5/10 , C12N5/0783 , A61K39/00
CPC分类号： C12N5/0636 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5156 , A61K2039/585 , C12N2501/515 , C12N2510/02 , C12N2511/00
摘要： The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
摘要翻译：本发明涉及修饰的T细胞，制备和使用分离的，修饰的T细胞的方法，以及使用这些分离的，修饰的T细胞来解决疾病和病症的方法。在一个实施方案中，本发明广泛涉及TCR缺陷的T细胞，其分离的群体，以及包含其的组合物。在本发明的另一个实施方案中，将这些TCR缺陷型T细胞设计为表达功能性非TCR受体。本发明还涉及制备所述TCR缺陷型T细胞的方法，以及使用所述TCR缺陷型T细胞，其群体或包含该T细胞的组合物减少或改善或预防或治疗疾病和病症的方法。

7. 发明申请

US20120321667A1 T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS 有权
公开(公告)号：US20120321667A1
公开(公告)日：2012-12-20
申请号：US13502978
申请日：2010-10-29
申请人： Charles L. Sentman
发明人： Charles L. Sentman
IPC分类号： C12N5/0783 , A61P31/00 , A61P35/00 , A61P37/06 , C12N5/10 , A61K35/12
CPC分类号： C12N5/0636 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5156 , A61K2039/585 , C12N2501/515 , C12N2510/02 , C12N2511/00
摘要： The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

8. 发明申请

US20120302466A1 T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS 有权
标题翻译： T细胞受体缺陷型T细胞组成
公开(公告)号：US20120302466A1
公开(公告)日：2012-11-29
申请号：US13459664
申请日：2012-04-30
申请人： Charles L. Sentman
发明人： Charles L. Sentman
IPC分类号： C12N5/0783 , C40B50/00
CPC分类号： C12N5/0636 , A61K2039/5156 , C12N2501/515
摘要： The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
摘要翻译：本发明涉及修饰的T细胞，制备和使用分离的，修饰的T细胞的方法，以及使用这些分离的，修饰的T细胞来解决疾病和病症的方法。在一个实施方案中，本发明广泛涉及TCR缺陷的T细胞，其分离的群体，以及包含其的组合物。在本发明的另一个实施方案中，将这些TCR缺陷型T细胞设计为表达功能性非TCR受体。本发明还涉及制备所述TCR缺陷型T细胞的方法，以及使用所述TCR缺陷型T细胞，其群体或包含该T细胞的组合物减少或改善或预防或治疗疾病和病症的方法。

9. 发明申请

US20120029063A1 CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER 有权
标题翻译： CHIMERIC NK受体和治疗癌症的方法
公开(公告)号：US20120029063A1
公开(公告)日：2012-02-02
申请号：US13155909
申请日：2011-06-08
申请人： TONG ZHANG , CHARLES L. SENTMAN
发明人： TONG ZHANG , CHARLES L. SENTMAN
IPC分类号： A61K48/00 , A61P35/00 , C12N15/85
CPC分类号： C07K14/705 , A61K35/17 , A61K38/10 , A61K45/06 , C07K14/715
摘要： The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
摘要翻译：本发明涉及用于减少或消除肿瘤的嵌合免疫受体分子。嵌合受体是与含有基于免疫受体酪氨酸的活化基序的免疫信号受体融合的C型凝集素样天然杀伤细胞受体或与其相关的蛋白质。还提供了使用嵌合受体的方法。

10. 发明申请

US20120294857A1 Monomeric Bi-Specific Fusion Protein 审中-公开
标题翻译：单体双特异性融合蛋白
公开(公告)号：US20120294857A1
公开(公告)日：2012-11-22
申请号：US13521532
申请日：2011-01-07
申请人： Charles L. Sentman , Tong Zhang
发明人： Charles L. Sentman , Tong Zhang
IPC分类号： C07K19/00 , C12N15/62 , A61P31/00 , C12N1/21 , C12N5/10 , A61P35/00 , A61K39/395 , C12N15/63
CPC分类号： C07K16/2809 , C07K14/70503 , C07K14/7056 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/33
摘要： The present invention embraces a bi-specific fusion protein composed of an effector cell-specific antibody-variable region fragment operably linked to at least a portion of a natural killer cell receptor. Methods for using the fusion protein in the treatment of cancer and pathogenic infections are also provided.
摘要翻译：本发明包括由与天然杀伤细胞受体的至少一部分可操作地连接的效应细胞特异性抗体可变区片段组成的双特异性融合蛋白。还提供了使用融合蛋白治疗癌症和致病性感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式